Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease

Nature Medicine

Volumn 20, Issue 5, 2014, Pages 536-541

  Wang, Nan ^a,b   Gray, Michelle ^a,b,e   Lu, Xiao Hong ^a,b   Cantle, Jeffrey P ^a,b   Holley, Sandra M ^a,b   Greiner, Erin ^a,b,c   Gu, Xiaofeng ^a,b   Shirasaki, Dyna ^a,b,c   Cepeda, Carlos ^a,b   Li, Yuqing ^d   Dong, Hongwei ^b,f   Levine, Michael S ^a,b   Yang, X William ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN ATROPHY; BRAIN CELL; BRAIN CORTEX; CELL POPULATION; CELLS BY BODY ANATOMY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSGENE; ANIMAL; BEHAVIOR; BIOSYNTHESIS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; MUTATION; PATHOLOGY;

ANIMALS; BEHAVIORAL SYMPTOMS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; HUNTINGTON DISEASE; MICE; MOTOR ACTIVITY; MUTATION; NERVE TISSUE PROTEINS; NEURONS;

EID: 84902996303     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3514     Document Type: Article

References (36)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
2. Vonsattel, J.P. & DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384 (1998).
3. Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182-6195 (2008).
4. Walker, F.O. Huntington's disease. Lancet 369, 218-228 (2007).
5. Tabrizi, S.J. et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42-53 (2012).
6. Kaltenbach, L.S. et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 11, e82 (2007).
7. Shirasaki, D.I. et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 75, 41-57 (2012).
8. Ilieva, H., Polymenidou, M. & Cleveland, D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187, 761-772 (2009).
9. Hadzi, T.C. et al. Assessment of cortical and striatal involvement in 523 Huntington disease brains. Neurology 79, 1708-1715 (2012).
10. Harper, S.Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102, 5820-5825 (2005).
11. DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. USA 104, 17204-17209 (2007).
12. Kordasiewicz, H.B. et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044 (2012).
13. Sah, D.W. & Aronin, N. Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest. 121, 500-507 (2011).
14. Menalled, L. et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 35, 319-336 (2009).
15. Gu, X. et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433-444 (2005).
16. Dang, M.T. et al. Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc. Natl. Acad. Sci. USA 103, 15254-15259 (2006).
17. Gorski, J.A. et al. Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J. Neurosci. 22, 6309-6314 (2002).
18. Iwasato, T. et al. Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature 406, 726-731 (2000).
19. Soriano, P. Generalized lacZ expression with the Rosa26 Cre reporter strain. Nat. Genet. 21, 70-71 (1999).
20. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133-140 (2010).
21. Schmidt, E.F. et al. Identification of the cortical neurons that mediate antidepressant responses. Cell 149, 1152-1163 (2012).
22. Matamales, M. et al. Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS ONE 4, e4770 (2009).
23. Zoghbi, H.Y. & Warren, S.T. Neurogenetics: advancing the "next-generation" of brain research. Neuron 68, 165-173 (2010).
24. Raymond, L.A. et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 198, 252-273 (2011).
25. Goto, S. & Hirano, A. Synaptophysin expression in the striatum in Huntington's disease. Acta Neuropathol. 80, 88-91 (1990).
26. Cepeda, C. et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23, 961-969 (2003).
27. Kuhn, A. et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16, 1845-1861 (2007).
28. Becanovic, K. et al. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum. Mol. Genet. 19, 1438-1452 (2010).
29. Wyszynski, M. et al. Competitive binding of α-actinin and calmodulin to the NMDA receptor. Nature 385, 439-442 (1997).
30. Dunah, A.W., Wyszynski, M., Martin, D.M., Sheng, M. & Standaert, D.G. α-actinin-2 in rat striatum: localization and interaction with NMDA glutamate receptor subunits. Brain Res. Mol. Brain Res. 79, 77-87 (2000).
31. Kennedy, M.B. The postsynaptic density at glutamatergic synapses. Trends Neurosci. 20, 264-268 (1997).
32. Fan, J., Cowan, C.M., Zhang, L.Y., Hayden, M.R. & Raymond, L.A. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J. Neurosci. 29, 10928-10938 (2009).
33. Crook, Z.R. & Housman, D. Huntington's disease: can mice lead the way to treatment? Neuron 69, 423-435 (2011).
34. Yang, X.W., Model, P. & Heintz, N. Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome. Nat. Biotechnol. 15, 859-865 (1997).
35. Lobo, M.K., Karsten, S.L., Gray, M., Geschwind, D.H. & Yang, X.W. FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. Nat. Neurosci. 9, 443-452 (2006).
36. Gu, X. et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64, 828-840 (2009).